PubMed · 2006 · 154 citations · 12 references
MedicineImmunologyOncologyCancer ImmunologyMetastasisTumor ProgressionCancer ImmunotherapyMalignant NeoplasmsMetastatic Breast CancerAllogeneic Cytotoxic T Lymphocyte ResponsesEstrogen Receptor SignalingHormone Receptor Positive Metastatic DiseaseMalignant Breast TumorsMetastasis ModelsMetastasis PathologyMetastatic Breast Cancer BiologyMetastatic Breast Cancer Treatment
BACKGROUND: Breast cancer treatments are most effective when initiated early, with very poor efficacy against metastatic disease. In seeking a readily metastasizing mouse breast cancer model to facilitate the search for effective therapies, E0771 medullary adenocarcinomas implanted subcutaneously in syngeneic C57BL/6 mice were studied. MATERIALS AND METHODS: Standard pathological, histological and immunological methodologies were used. RESULTS: The aggressive estrogen receptor-positive tumor invaded locally into the peritoneal cavity in 56% of mice, as well as metastasizing to the lungs in 52% of mice. The metastasis was a spontaneous event and immunosuppression was seen (e.g. generation of lyphokine activated killer cells and allogeneic cytotoxic T lymphocytes cytolytic activities ex vivo were suppressed). Other pathological events noted as the tumor progressed were: bloody ascites (56%) and shock (72%), both attributed to local (peritoneal) tumor invasion. CONCLUSION: The E0771 metastatic breast cancer model, which mimics the human disease, should be useful in testing new treatments against this disease and/or in examining the metastatic process.
12
Systemic and local immunosuppression in pancreatic cancer patients.
Wolfram von Bernstorff, Martina Voss, Susanne Freichel et al. · PubMed · 2001 · 281 citations
Life Sciences, Immunology, Oncology +17
Long-term survivors after breast cancer
J. Michael Dixon, David L. Page, Thomas Anderson et al. · British journal of surgery · 1985 · 98 citations